NephrosNEPH +1.78%62 Days Payable is 48.87 as of Mar. 2026, which is 31% below its 10-year median of 71.07. GuruFocus rates NEPH with a GF Score™ of 62/100 and a GF Value™ of $2.88 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 795 Medical Devices & Instruments companies, Nephros ranks worse than 73.08% on this metric.
Nephros's average Accounts Payable for the
three
months ended in Mar. 2026 was $1.19 Mil. Nephros's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $2.22 Mil.
Hence, Nephros's Days Payable for the
three
months ended in Mar. 2026 was 48.87.
The historical rank and industry rank for Nephros's Days Payable or its related term are showing as below:
NEPH'
s Days Payable Range Over the Past 10 Years
Min: 39.82 Med: 71.07 Max: 220.03
Current: 42.9
During the past 13 years, Nephros's highest Days Payable was 220.03. The lowest was 39.82. And the median was 71.07.
NEPH's Days Payable is ranked worse than 73.08% of 795
companies
in the Medical Devices & Instruments industry
Industry Median: 68.07
vs NEPH: 42.90
Nephros's Days Payable
increased
from Mar. 2025 (31.93) to Mar. 2026 (48.87).
It may suggest that Nephrosdelayed paying its suppliers.
Nephros Days Payable Related Terms
Nephros Days Payable Historical Data
* Premium members only.
The historical data trend for Nephros's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nephros's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephros Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Days Payable distribution charts can be found below:
* The bar in red indicates where Nephros's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Nephros's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nephros (NEPH) has a Days Payable of 48.87 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nephros and its competitors. This is 31% below median its historical median of 71.07. Over the past decade, Nephros' Days Payable has ranged from 39.82 to 220.03. According to the industry distribution chart, Nephros ranks #581 out of 795 companies in the Medical Devices & Instruments industry, placing it in the top 73.1%.
Is Nephros' Days Payable too high?
Nephros' current Days Payable of 48.87 is 31% below median its 10-year median of 71.07. Over the past 10 years, this metric has ranged from a low of 39.82 to a high of 220.03. The Medical Devices & Instruments industry median Days Payable is 68.07. Nephros' value of 48.87 is 28.2% below this industry median. Based on the distribution chart, Nephros ranks #581 out of 795 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Nephros has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nephros' Days Payable compare to MLSS and RGNT?
According to the Medical Devices & Instruments industry distribution chart, Nephros ranks #581 out of 795 companies for Days Payable. This places Nephros in the lower half of its industry. The industry median Days Payable is 68.07. Nephros' value of 48.87 is 28.2% below this benchmark. Historically, Nephros' own Days Payable has ranged from 39.82 to 220.03 over the past decade. While the company's 10-year median is 71.07 vs. the industry median of 68.07, Nephros has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 68.07, based on 795 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nephros's current Days Payable of 48.87 is 28.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Nephros and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 68.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nephros's current Days Payable is 48.87, which is 31% below median its own 10-year median of 71.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nephros stock overvalued right now?
Based on GuruFocus' analysis, Nephros (NEPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $2.88, compared to a current price of $3.72 — trading 29% above its estimated fair value. The current Days Payable is 48.87, which is 31% below median its 10-year median of 71.07 and 28.2% below the Medical Devices & Instruments industry median of 68.07. Nephros' overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Nephros (NEPH), the current Days Payable is 48.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nephros (NEPH) Overvalued in 2026?
Based on GuruFocus' analysis, Nephros stock appears to be overvalued.
The current stock price of $3.72 is trading 29% above its estimated GF Value™ of $2.88.
GuruFocus considers Nephros to be Modestly Overvalued.
Key valuation signals for NEPH:
Days Payable: 48.87 (31% below median its 10-year median of 71.07)
GF Value™: $2.88 vs. price of $3.72 (29% above fair value)
Industry Position: 28.2% below the Medical Devices & Instruments median (#581 of 795)
No single metric tells the full story. See the NEPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.
62GF Score
Get the complete analysis for NEPH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NEPH has been successfully added to your 
